Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
CJC-1295 (with or without DAC)
Also known as: CJC-1295 DAC, CJC-1295 no DAC, Modified GRF(1-29)
Confidence
Updated 2026-03-18
CJC-1295 is a synthetic analog of GHRH(1-29) with modifications to extend its half-life. Available in two forms: with Drug Affinity Complex (DAC) for prolonged action, and without DAC (also called Modified GRF 1-29) for shorter, more pulsatile action. Frequently combined with ipamorelin for synergistic GH release.
Class
GH Secretagogue
Routes
Subcutaneous
Half-Life
With DAC: ~8 days | Without DAC (Mod GRF): ~30 minutes
Binds to GHRH receptors on pituitary somatotrophs to stimulate growth hormone release. The DAC modification creates covalent binding to serum albumin, dramatically extending half-life. The no-DAC version provides more physiologic pulsatile GH release patterns.
Half-Life
With DAC: ~8 days | Without DAC (Mod GRF): ~30 minutes
Bioavailability
Not established in formal human PK studies.
No approved indications. Studied for growth hormone deficiency assessment, anti-aging, body composition, recovery, sleep quality.
Human endocrine effects are real and measurable — CJC-1295 with DAC consistently elevates IGF-1 levels by 2-10x in human studies. However, clinical outcome benefits beyond biomarker changes are not established in RCTs. The physiological risk profile is better characterized than many Category 2 peptides.
Human Studies
8
Animal Studies
25
Common: flushing, headache, dizziness, injection site reactions. Potential: water retention, carpal tunnel syndrome, joint pain (GH-mediated). Concern: sustained GH elevation with DAC version may increase IGF-1 to supraphysiologic levels. Unknown long-term cancer risk with chronic GH elevation.
PCAC rejected inclusion on 503A list (December 2024). Remains prohibited for routine compounding despite removal from Category 2 procedurally.
Drug Interactions: May interact with glucose-lowering medications. Concurrent glucocorticoids may blunt response. Research Gaps: No RCTs for anti-aging outcomes. Cancer risk with chronic GH elevation is a theoretical concern requiring long-term study.
Subcutaneous (research context)
Common Range
100–300 mcg/dose (no DAC); 2mg/week (with DAC)
Timing
Before bed or post-workout (no DAC)
Frequency
No DAC: 1–3x daily | With DAC: 1–2x weekly
Cycling
8–12 weeks on, 4 weeks off
Reconstitution
Bacteriostatic water
Storage
Refrigerated
Important Note
Commonly combined with Ipamorelin. NOT FDA-approved, cannot be legally compounded.
Connect with a verified provider offering CJC-1295 therapy near you.
GH Secretagogue
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to stimulate GH release from the pituitary. It is considered one of the most selective GH secretagogues, with minimal effect on cortisol, prolactin, and other hormones — making it a preferred choice in combination protocols with CJC-1295.
GHRH Analog
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. Originally FDA-approved for diagnostic use in assessing growth hormone secretion, it has become a cornerstone of legitimate peptide therapy for growth hormone optimization due to its established safety profile and compounding eligibility.
GHRH Analog
Tesamorelin is a synthetic GHRH analog that is the only FDA-approved peptide therapy specifically for the reduction of excess abdominal fat. Originally approved for HIV-associated lipodystrophy, it has gained significant attention in the anti-aging and metabolic optimization space as a legal, well-characterized GH secretagogue.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.